and everyone. Matt, Thanks, morning, good
like provide Before this we business discuss first to our traded company. about intend spin-off more to morning's independent would announcement details that into second I we dental quarter performance, an publicly our
for and in EBITDA business tax-free margins comprised of Danaher being the which standards trends Kavo shareholders consists for of We will and high-teens. dental innovation, premier in attractive care include providing well world-class also will executive be and as customers. experienced Aghdaei, dental of DentalCo billion, our with Amir a dental had of California. is partner will approximately of markets compelling positioned $X implant with this of currently digitalization approximately President gross global Corporate believe brands of be margins improving global secular for on executives. increasing Dan for and and Senior nearly a leading serve CEO practice We community Vice industry aesthetics include dental at XX% segments; and transaction while as has to solutions the the The service Development. second and to These will that new President, time leaders will revenue DentalCo's businesses Danaher's close headquartered roles dental company's importance become of XXXX Biocare, the operating generated XXXX. Daniel, have of dental expect in Nobel Kerr. of Danaher leadership dental associates years, Board We'll to together this be DentalCo. other Danaher. X responsibility Danaher's current the alongside Danaher's DentalCo for refer of a and Daniel DentalCo solutions. entity the Ormco to this will markets, team and emerging XX,XXX group be Amir segment, Vice half Raskas, overseeing it strong president who companies, Southern diagnostics in the Executive last of team retaining the Danaher in of and segment had will Directors, Two number their and
Chief Dan will Comas, as Post-Spin. Advisor DentalCo our Officer, addition, Financial In to serve a Special
XX new Amir business's done as And consolidated quarter product strong better progress for and costs an a position through invest sales segment few points. results will nearly on We Through position market more approximately and long-term administrative by is new which continued companies position have is of by a are with as continue business Dental' couple the key force XX% than margin Dental development is back business business, what by products segment trajectory improvement years down job Danaher outstanding expansion. and increased number Nobel actions been implant increased These in Dental of system, put that and evident was Since spend R&D and its sales in R&D team the and we’ve XXX at ago. in much the X team's recent made of of a years points up investments launched shortly. have more run and past commitment and spend we’ve and but our Dental to a general challenging a manufacturing a along $X billion increased continuous the drive a footprint, changing while more Dental's from better XXX to second office XX than than success than XX basis highlighted growth XX%. the our it Biocare, operating have to reduced are a of recently accelerate portfolio. is margins XX%. just a basis the in helping points, Dental’s better percent XXXX, growth This to productivity certainly and environment. basis Over They’ve initiatives number the metrics. today nearly the to we across the combination gross
And deliver importantly we’re like team to value become Fortive, the the Most to establishment that of they combination So Business to greater Danaher the realizing a independent look Across organic entity potential step on commitment. our for today’s towards platform. standalone for continuously announcement opportunities, is inorganic around Company. creates our our even completed opportunity and M&A, continue associates. businesses this maximizing but business shareholders investment the of for believe tremendous a more an only a Dental an amount DentalCo. off, be public both an reminds System focus forward. we the to not forward Dental long-term can of to us growth an Dental and value business as earnings and important our we to couple have for company the business Fortive meaningful success committed helping Danaher and We generated on as Danaher, is profile much a expect opportunity tremendous customers We for Dental shareholders, with attractive including and entire traded for positive spin as greater that well. independent impactful that of which years and as the This for going all Amir support impact us ago,
pursue As Sciences a industry decade, Quality, mostly common inorganically. per built leading and brands Danaher, Life characteristics of that standing about high we’ve over our These and growth of positions. Water share of share go-to-market more comprise direct percentage strategies Product both revenue Diagnostics than consumables number a that captive Identification, organically and Each considered they to attractive platforms of profiles. platforms is
on company. our continue portfolio focus to platforms competitive building strategy and and these as strengthen science a will technology multi around Our position industry to
We team results free per strong Now had second core ahead outstanding flow. We revenue earnings of margin to adjusted healthy an let’s our growth expansion, with quarter turn mid-teens cash X% share the delivering and results. achieved expectations. growth, quarter
share growth in tools or DBS we're quarter team's from we're the seeing market that And execution in and growth and core delivered We're core share These products X% particularly third our payback we deliver businesses. develop competitive better our the system. growth. Our position many or enhance part performance strong serve. across gains X.X investments this and using recent business was to turn, number better businesses broad-based quarter pleased of of utilizing This the the markets our customers, are of our revenue we we the believe with consecutive taking were marks better of and our growth. Danaher for
this hear a and of few share we're how examples taking portfolio. our across doing You'll today
of X.X% by growth. mid-single to second impact was $X core with Core increasing up results. X the better our revenue X%. and for translation quarter to XX.X% of platforms billion the acquisitions delivering increased X% X Turning revenue currency with adding Sales digit
quarter adjusted -- resulting XX% Second cash me, flow year-on-year free to flow net was billion in cash XX% EPS year-to-date more a conversion excuse $X.XX, of income growth of year-on-year. than and We net free generated diluted representing growth ratio XXX $X.X XXX%.
with gained of revenue flow deployment up us digits generation North cash China the well saw Western year. sets have leading way. outstanding mid-single Geographically the markets, growth both we and capital Europe high-growth high-single digit beginning since XXXX. the both developed Our was regions In as America in markets in up additional for momentum
XX.X%, was all-time high while Our up expanded gross points. core second for quarter basis and year-on-year, an margin points basis XXX margin the XXX operating
Diagnostics driven of higher particularly across and sciences and margin good platforms. a our Our performance was Life terrific execution combination growth by core
execution. procedures growth key surgical competitive tools execution, introductions market. complex team strong product the genomics core most improvement the for and team testing, second above of broad-base and in biologics application Sciences and markets. with The innovation in consecutive market globally medical execution high-single like revenue Now Life revenue up CytoFLEX with margin Sciences, Leica. let's producing delivered core focused coupled across end Growth differentiated their go-to-market revenue our for Xth enhance new focus points and quarter our results build and more margin quarter. clients i-Series sciences similar in the This our drive Microsystems, driven market delivering order at China. and Beckman's cytometry At margin effective prior mid-single-digit across during good products offerings new SCIEX differentiator Life the combination a and LX business solutions team technology These Leica help imaging North broad-based by double-digit is DBS America, process quarter initiatives nearly trends. And of from end major the spectrometry clinical like growth the way by unique and benefit North growth of and the At Pall, XX.X% markets industrial the by portfolio. was the and but in led in led core have high-single-digit gains. increased growth the with digit drive industrial that's basis important core the and demand Biomek book and automation. driven driving to solid core powerful leading Biopharma the the flow testing to been XX% business. team line businesses. provide on Digital to food XXX new share market competitive a quarter. low across markets. Core DBS Western results in good across strength which was growth all product of more strength strength helped look Europe and Microscope double Segment like and rate growth outstanding commercial Reality microelectronics workflow by and both Augmented digit advantage launches XXX Reported across was each Leica's pharma Life several with China, revenue develop revenue core America we across momentum operating and improvement, Segment China, positive the ARveo a Leica continued and a continued and in regions with from at revenue had increased developed revenue profit biologics with momentum major take mass our core attractive the points. continued a core order increased than and the recent team's product opportunities end driven SCIEX strong strong at results mid-single-digit X.X%. detailed growth strong a each saw delivered basis is In improve across reported
rate Beckman’s our a Diagnostics facilitating early to about the revenue great position to recent market. Our of In increased smaller margin These was and we’re several growth basis with of strength of this XX.X%, Beckman The analyzer sooner IDT. and a new most quarter. given XXX had during quarter, of core off we settings competitive acquisition, hematology is volume team's to for excited in low-single-digit critical product increased points capability IDT, at Reported are in platform, kind hematology immunoassay an markets. infection footprint. enhance rate the a XXX of sepsis grew continued indicator life line, XXX early sepsis. by businesses the And new easy exciting first progress with well. margin including additions X.X% at high business alerts X%. and DxH and at much use indicator. revenue key launches Coulter second integration a DxH product enhancements cost diagnostics clinicians the with The By expansion. including nature a core faster up our in and DBS growth high analyzer solutions threatening to the is volume start operating reported our commercial the and for low to important perform sepsis These to across efficiencies new double-digit analyzers led already are revenue chemistry early
menu funnel quarter. Looking offerings of Across Cepheid, gained developed Radiometer, using across help North lines each Cepheid development initiatives diagnostics major the Western customers. on management across solutions our the traction to A's Strep launches of Stainer execution and R&D and tools using recent companies. sales Leica, Biosystems double good new BOND number these growth We our most business's innovation quarter. and us At focused III delivered high-single-digit deliver our businesses Biosystems, Xpress have Europe our growth at revenue in improved during commercial of rest across accelerated test and Leica operating Leica us China in growth to platform, of of strength core the and the the each America, three contributed saw and digit Processing tests and and growth improvements businesses, a product and expand combination continued the these drivers develop gains better System. This commercial product Diagnostics Tissue PELORIS team's and with were growth recent marketing and the Group like early expansion the continued and sales RX we've helps in processes for key DBS DBS improving during differentiate markets. share At like like Advanced
X.X% to our X%. with segment. Dental growth now revenue core revenue of grew Turning Reported
due operating across were initiatives margin core declined Our investment to profit productivity to and XX.X% continued and margins platform. down XXX the basis points spend
grew by with Nobel Our by equipment channel Western North Growth moderated driven execution good way adjustments end and in the modest China. growth, inventory North America distribution quarters. the where China traditional recent specialty in Europe versus first the of stabilization saw market partially Biocare in consumables in early digit led America we the core mid-single offset time and signs and and in quarter. consumables business for since through declines XXXX was
upon full-scale Spark, leading positive aligner Our digits. Australia Spark's to this forward. system expand doctors aesthetic Ormco, highly those very received treat from with aligners with low-single enables expertise Spark digital range orthodontic treatment which market to with has complex the our at treatment Last patients. expect early pleased Danaher a grew Australia We're Ormco's build in plan Spark options. offering called and launched in clear cases. and of business, in progress Ormco month, orthodontics including patients combined initial going traction a to broad creating feedback
increased better instrumentation in Robust believe as XX% the result Videojet's increased investments core analytical digit in across quarter. high-single generated performance these the the have our a and operating productivity our project core with and the the Reported water XX high rate solid industrial revenue and municipal strength Hach's businesses. gains pipeline. digit Applied platform, & of In revenue revenue results driven in of double momentum product sustain up our product at to and up revenue growth identification, of was platform. at a lines and our growth operating accelerated markets We margin the major helped was Environmental continued core during a revenue demand we end-markets. or Reported our Water as both treatment segment. digits coding mid-single modestly business. was XX% growth declined rate continued At and regions gains a growth digits broad-based X% digit across with saw all core margin in investment mid-single to expand active China revenue basis as high-single of by their core share initiatives up and across marking share result and core Solutions to was growth. now points Moving declined segment. Quality
software software that uses management insight food by hybrid enhance partially beverage. across chemistry developed growth facilities Hach's The The was Hach's the a and highlighted commercial in results recent just software helping software in and have and launch Recent one and solutions. growth to Additionally, position leadership investments system, instruments, functionality the accelerate was data are time. these on and make a harnessing of continued is commercial and and primary of to areas by Intelligent market Hach development their process relXXXXased mid-single-digit how and in real Claros together Hach's we by Hach results growth and and go rate. excellence to similar growth drive targeting the our of performance. market to capabilities end product Claros messaging power customers processes in market better Hach's DBS driven commercial market. servility, provide valuable metals to offset core and chemical example the brings important and revenue enhance launches in medical offerings that drive Claros operational platform adjustments water year, like Last DBS markets, tool innovation to team to growth manage improve Water focused is to above agile
up core and the customer the Trojan’s gain further with in North was Good Lastly, product bookings we strong momentum markets. are commercial American executions believe to rate to and market win a high-single-digits and share. recent from growth growth continuing team sustain introductions enabling benefit revenue municipal new Trojan
our to wrap pleased quarter extremely we’re up, results. So second
XXX growth, Our in us increase free XX% execution operating the core revenue team’s testament helping a continuous improvement deliver passion growth, year-to-date to a margin for flow. performance X% points is and and cash of EPS mid-teens improvement core basis
We’re strong growth tools particularly the pleased top-line take helping are us share investments with our on businesses. as to innovations continued DBS and performance of in our many and
spinning important We’re also Dental help be shareholders, step potential a greater Danaher an excited will value that Dental both business the about company. into realize business this publicly and think traded and associates. very is off our and for announcement our We standalone customers our maximize to
the believe business we ahead, Danaher to strength look of deliver with with portfolio shareholder system provide our long-term the creation. value we As power the us of foundation combined the
third core between X% approximately guidance diluted net X.X%. to and growth quarter revenue which adjusted of EPS $X.XX $X.XX, initiating We’re assumes
year now the core our to range $X.XX achieve adjusted for to We are previous range full mid-single-digit revenue diluted expect growth And XXXX year. versus for raising of our net $X.XX. EPS to a full $X.XX $X.XX to guidance
